INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) investors concerning the Company’s possible violations of federal securities laws.
On April 1, 2024, Ocugen disclosed that it had identified certain accounting errors related to certain agreements with one of its business partners regarding a collaboration agreement. The Company also disclosed that its previously-issued financial statements for each fiscal year beginning January 1, 2020 should no longer be relied upon and will be restated.
On this news, Ocugen’s stock price fell $0.16, or 10.4%, to close at $1.38 per share on April 2, 2024, thereby injuring investors.
If you purchased Ocugen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847 or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240412811875/en/
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
What the Fed’s QT Program Is, and Why Its End Matters
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?